Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 6;2(3):100099.
doi: 10.1016/j.jhepr.2020.100099. eCollection 2020 Jun.

Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis

Affiliations

Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis

Lorraine McSweeney et al. JHEP Rep. .

Abstract

Background & aims: Non-alcoholic steatohepatitis (NASH) is known to have a negative impact on patients' health-related quality of life (HRQoL), even before progression to cirrhosis has occurred. The burden of NASH-related cirrhosis from the patient perspective remains poorly understood. Herein, we aimed to identify the burden of disease and HRQoL impairment among patients with NASH-related compensated cirrhosis.

Methods: This targeted literature review sought first to identify the humanistic burden of disease from the perspective of patients with diagnosed NASH-cirrhosis and, secondly, to identify generic or disease-specific patient-reported outcome measures (PROMs) used to assess the impact of NASH-cirrhosis. Searches were conducted in bibliographical databases, grey or unpublished literature, liver disease websites, support group websites and online blogs. A quality assessment of specific PROMs was conducted.

Results: Patients with NASH-cirrhosis are reported to suffer from lower HRQoL than patients with non-cirrhotic NASH and the general population with respect to physical health/functioning, emotional health and worry, and mental health. Thirteen PROMs were identified, of which 4 were liver-disease specific: CLDQ, CLDQ-NAFLD, LDQoL and LDSI. The most commonly used measures do not comply with current industry or regulatory standards for PROMs and/or are not validated for use in a cirrhotic NASH population.

Conclusions: Patients with NASH-cirrhosis have lower HRQoL and poorer physical health than patients with non-cirrhotic NASH. However, the literature lacked detail of the everyday impact on patients' lives. Currently, a number of PROMs are available to measure the impact of the disease in patients with chronic liver conditions. The lack of studies that include qualitative insights in this population mandates further exploration and research.

Lay summary: It is not well understood how having non-alcoholic fatty liver disease (NAFLD)-related cirrhosis affects a person's everyday wellbeing and quality of life. Some research has been done with patients who have early stages of liver disease but not people with cirrhosis. We found that patients with NAFLD-related cirrhosis tended to have poorer health than patients without cirrhosis. But there was not very much information from patients themselves and there were no tools or questionnaires just for this group of patients.

Keywords: CLDQ, chronic liver disease questionnaire; COSMIN, The COnsensus-based Standards for the selection of health Measurement INstruments; Cirrhosis; EMA, European Medicines Agency; FDA, United States Food and Drug Administration; FIS, fatigue impact scale; HRQoL, health-related quality of life; LDQoL, liver disease quality of life questionnaire; LDSI, liver disease symptom index; MS, multiple sclerosis; NAFL, non-alcoholic fatty liver; NAFLD; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; Non-alcoholic steatohepatitis; PHAQ, patient-reported outcome measurement information system health assessment questionnaire; PRO, patient-reported outcome; PROM, patient-reported outcome measure; QoL, quality of life; RI, researcher interpretation; SF-36, short form health profile 36; health-related quality of life; liver; patient-reported outcome measures.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
PRISMA flow diagram: for objective (a) — humanistic burden of NASH-cirrhosis. 3,015 records were identified from databases. After removal of duplicates, 1,809 records were screened. Eligibility assessment of texts, plus 5 grey literature studies, resulted in 31 studies being included in the humanistic burden of NASH-cirrhosis synthesis.
Fig. 2
Fig. 2
PRISMA flow diagram: for Objective (b) — PROMs F4. A second database search identified a further 545 studies in addition to search one (objective (a)). After removal of duplicates, 2,355 records were screened. Eligibility assessment of texts resulted in 20 studies being included in the PROMs synthesis.

References

    1. Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. - PubMed
    1. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–344. - PubMed
    1. McPherson S., Hardy T., Henderson E., Burt A.D., Day C.P., Anstee Q.M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–1155. - PubMed
    1. Dulai P.S., Singh S., Patel J., Soni M., Prokop L.J., Younossi Z. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565. - PMC - PubMed
    1. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. - PubMed